

Status: Currently Official on 13-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-66A00DF6-E2B4-4188-AB2B-B04A394C648F_5_en-US
DOI: https://doi.org/10.31003/USPNF_M2659_05_01
DOI Ref: z7oeu

© 2025 USPC
Do not distribute

Almotriptan Tablets

DEFINITION

Almotriptan Tablets contain an amount of almotriptan malate ($C_{17}H_{25}N_3O_2S \cdot C_4H_6O_5$) equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of almotriptan ($C_{17}H_{25}N_3O_2S$).

IDENTIFICATION

Change to read:

- A. [▲ SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy: 197F](#) ▲ (CN 1-MAY-2020)

Sample: Sonicate 5 powdered Tablets in 25 mL of water. Extract the suspension with 25 mL of [methylene chloride](#), and discard the organic phase. Add another 25 mL of [methylene chloride](#) and 3 mL of [1 N sodium hydroxide](#). Extract the precipitated base into the organic layer. Dry with [anhydrous sodium sulfate](#), and evaporate the organic solvent. Prepare the residue oil as a film on a sodium chloride pellet.

Acceptance criteria: The IR spectrum obtained from the *Sample* is consistent with that of similarly prepared [USP Almotriptan Malate RS](#).

- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Protect samples, the Reference Standards, and solutions containing them from light.

Buffer: Add 10 mL of [triethylamine](#) to every 1000 mL of [0.01 M phosphoric acid](#). Adjust with [phosphoric acid](#) to a pH of 6.0.

Mobile phase: [Acetonitrile](#) and *Buffer* (10:90)

Standard solution: 0.5 mg/mL of [USP Almotriptan Malate RS](#) in *Mobile phase*. Sonication may be used to aid in dissolution.

System suitability stock solution: 0.1 mg/mL each of [USP Almotriptan Related Compound B RS](#), [USP Almotriptan Related Compound C RS](#), and [USP Almotriptan Related Compound D RS](#) in [methanol](#). Sonication may be used to aid in dissolution.

System suitability solution: 0.001 mg/mL each of [USP Almotriptan Related Compound B RS](#), [USP Almotriptan Related Compound C RS](#), and [USP Almotriptan Related Compound D RS](#) prepared from the *System suitability stock solution* in *Standard solution*

Sample solution: Nominally 0.5 mg/mL of almotriptan from Tablets prepared as follows. Transfer NLT 8 Tablets into a suitable volumetric flask, and add 80% of the flask volume of *Mobile phase*. Sonicate for NLT 10 min, and dilute with *Mobile phase* to volume. Stir for 30 min, and centrifuge. Pass a portion of the supernatant through a suitable filter of 0.45-µm pore size. Use the filtrate.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 210 nm

Column: 2.1-mm × 10-cm; 1.8-µm packing [L1](#)

Column temperature: 40°

Flow rate: 0.55 mL/min

Injection volume: 3 µL

System suitability

Samples: *Standard solution* and *System suitability solution*

[NOTE—See [Table 1](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 1.5 between almotriptan related compound C and almotriptan peaks, *System suitability solution*

Tailing factor: NMT 3.0, *Standard solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of almotriptan ($C_{17}H_{25}N_3O_2S$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response of almotriptan from the *Sample solution*

r_S = peak response of almotriptan from the *Standard solution*

C_s = concentration of [USP Almotriptan Malate RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of almotriptan in the *Sample solution* (mg/mL)

M_{r1} = molecular weight of almotriptan, 335.46

M_{r2} = molecular weight of almotriptan malate, 469.55

Acceptance criteria: 90.0%–110.0% of the labeled amount of almotriptan

PERFORMANCE TESTS

• [DISSOLUTION \(711\)](#)

Test 1

Medium: [0.1 N hydrochloric acid](#); 900 mL

Apparatus 2: 50 rpm

Time: 15 min

Standard solution: ($L/600$) mg/mL of [USP Almotriptan Malate RS](#) in *Medium*, where L is the label claim in mg/Tablet

Sample solution: Pass a portion of the solution under test through a suitable filter of 0.45- μ m pore size.

Instrumental conditions

Mode: UV

Analytical wavelength

For Tablets labeled to contain 6.25 mg: 228 nm

For Tablets labeled to contain 12.5 mg: 284 nm

Blank: *Medium*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of almotriptan ($C_{17}H_{25}N_3O_2S$) dissolved:

$$\text{Result} = (A_u/A_s) \times (C_s/L) \times V \times (M_{r1}/M_{r2}) \times 100$$

A_u = absorbance of the *Sample solution*

A_s = absorbance of the *Standard solution*

C_s = concentration of [USP Almotriptan Malate RS](#) in the *Standard solution* (mg/mL)

L = label claim (mg/Tablet)

V = volume of *Medium*, 900 mL

M_{r1} = molecular weight of almotriptan, 335.46

M_{r2} = molecular weight of almotriptan malate, 469.55

Tolerances: NLT 80% (Q) of the labeled amount of almotriptan ($C_{17}H_{25}N_3O_2S$) is dissolved.

Test 2: If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.

Medium: [0.1 N hydrochloric acid](#); 900 mL

Apparatus 2: 50 rpm

Time: 30 min

Standard stock solution: 0.425 mg/mL of [USP Almotriptan Malate RS](#), equivalent to 0.30 mg/mL of almotriptan, in [water](#)

Standard solution: 0.021 mg/mL of [USP Almotriptan Malate RS](#), equivalent to 0.015 mg/mL of almotriptan, from the *Standard stock solution* in *Medium*

Sample solution: Pass a portion of the solution under test through a suitable filter of 0.45- μ m pore size, and discard the first 5 mL. Use the remaining filtrate.

Instrumental conditions

(See [Ultraviolet-Visible Spectroscopy \(857\)](#).)

Mode: UV

Analytical wavelength: 283 nm

Blank: *Medium*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of almotriptan ($C_{17}H_{25}N_3O_2S$) dissolved:

$$\text{Result} = (A_u/A_s) \times (C_s/L) \times V \times (M_{r1}/M_{r2}) \times 100$$

- A_U = absorbance of the *Sample solution*
- A_S = absorbance of the *Standard solution*
- C_S = concentration of [USP Almotriptan Malate RS](#) in the *Standard solution* (mg/mL)
- L = label claim (mg/Tablet)
- V = volume of *Medium*, 900 mL
- M_{r1} = molecular weight of almotriptan, 335.46
- M_{r2} = molecular weight of almotriptan malate, 469.55

Tolerances: NLT 80% (Q) of the labeled amount of almotriptan ($C_{17}H_{25}N_3O_2S$) is dissolved.

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

IMPURITIES

- ORGANIC IMPURITIES**

Mobile phase, Standard solution, System suitability solution, Sample solution, Chromatographic system, and System suitability: Proceed as directed in the Assay.

Analysis

Samples: *Standard solution, System suitability solution, and Sample solution*

Chromatograph the *System suitability solution* and identify the components on the basis of their relative retention times, as shown in [Table 1](#).

Calculate the percentage of each degradation product in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

- r_U = peak response of each degradation product from the *Sample solution*
- r_S = peak response of almotriptan from the *Standard solution*
- C_S = concentration of [USP Almotriptan Malate RS](#) in the *Standard solution* (mg/mL)
- C_U = nominal concentration of almotriptan in the *Sample solution* (mg/mL)
- M_{r1} = molecular weight of almotriptan, 335.46
- M_{r2} = molecular weight of almotriptan malate, 469.55

Acceptance criteria: See [Table 1](#).

Table 1

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Spiroalmotriptan ^a	0.32	0.4
2-Hydroxyalmotriptan ^b	0.47	0.2
Almotriptan related compound B ^c	0.82	—
Almotriptan related compound C ^c	0.93	—
Almotriptan	1.0	—
Almotriptan related compound D	1.39	0.2
Any individual unspecified degradation product	—	0.2
Total degradation products	—	1.0

- a 1-Methyl-5-[(pyrrolidin-1-ylsulfonyl)methyl]spiro[indoline-3,3'-pyrrolidin]-2-ol.
- b 3-[2-(Dimethylamino)ethyl]-5-[(pyrrolidin-1-ylsulfonyl)methyl]-1*H*-indol-2-ol.
- c This is a process impurity that is included in this table for identification only. This impurity is controlled in the drug substance. This impurity is not to be reported for the drug product and is not to be included in the total degradation products.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers. Store at controlled room temperature.
- **LABELING:** The labeling states the *Dissolution* test used only if *Test 1* is not used.
- **USP REFERENCE STANDARDS (11).**

USP Almotriptan Malate RS

USP Almotriptan Related Compound B RS

2-{5-[(Pyrrolidin-1-ylsulfonyl)methyl]-1*H*-indol-3-yl}ethanamine hemifumarate.
 $C_{15}H_{21}N_3O_2S \cdot \frac{1}{2}C_4H_4O_4$ 365.46

USP Almotriptan Related Compound C RS

N-Methyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1*H*-indol-3-yl}ethanamine.
 $C_{16}H_{23}N_3O_2S$ 321.44

USP Almotriptan Related Compound D RS

1-[(3-[2-(Dimethylamino)ethyl]indol-5-yl)methyl)sulfonyl]pyrrolidine *N*-oxide hydrochloride.
 $C_{17}H_{25}N_3O_3S \cdot HCl$ 387.92

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ALMOTRIPTAN TABLETS	Documentary Standards Support	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 40(3)

Current DocID: **GUID-66A00DF6-E2B4-4188-AB2B-B04A394C648F_5_en-US**

DOI: <https://doi.org/10.31003/USPNF.M2659.05.01>

DOI ref: [z7oeu](#)